Thyroid eye disease (TED) therapy Tepezza – the very best asset in Amgen's $26 billion takeover of Horizon in 2023 – may very well be struggling with Levels of competition from A better-to-dose option from Sling Therapeutics. Zeidan was previously the Main progress officer at